Small molecule · developed by Novartis Pharmaceuticals
QVM149 is a once-daily inhaled combination of indacaterol acetate 150 µg, glycopyrronium bromide 50 µg and mometasone furoate 160 µg, delivered via Breezhaler. It is studied in asthma.
Summary written with AI from the sources listed at the end of this page.
Asthma
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →